Serono announced the discontinuation of two phase 3 clinical trial programs; onercept (recombinant tumor necrosis factor binding protein) in moderate-to-severe psoriasis and Canvaxin in Stage IV melanoma, licensed from CancerVax.
WebProWorld
Headline
Tag: serono
Back To Top